Cooperative Assessment of Late Effects for SCD Curative Therapies
Launched by VANDERBILT UNIVERSITY MEDICAL CENTER · Nov 29, 2021
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the long-term effects of curative therapies for Sickle Cell Disease (SCD), a condition that affects the blood and can lead to serious complications in the heart, lungs, and kidneys. The goal is to find out if these new therapies improve or worsen health problems in these organs compared to standard treatments. Researchers also want to see if certain genes might influence how well patients do after receiving curative therapies.
To be eligible for this trial, participants must have a confirmed diagnosis of SCD and be able to provide information about their health before and after treatment. They should be between the ages of 14 and 23 and can be of any gender. Participants will be asked to share their experiences and health data, which will help doctors understand the best treatment options for individuals with SCD. It's important to know that the trial is currently recruiting participants, and those who join will contribute valuable information that could lead to better care for future patients.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • Confirmed laboratory diagnosis of SCD
- • Ability to give informed consent
- • Ability to provide pre- and post-curative therapy data
- • Treated with either one HSCT or with standard disease-modifying therapy
- • Exclusion Criteria
- • •History of non-compliance
About Vanderbilt University Medical Center
Vanderbilt University Medical Center (VUMC) is a leading academic medical center located in Nashville, Tennessee, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, VUMC integrates cutting-edge scientific inquiry with patient-centered care, supporting a diverse array of studies aimed at enhancing medical knowledge and improving treatment outcomes. With a robust infrastructure and a multidisciplinary team of experts, VUMC fosters collaboration across various fields, ensuring the highest standards of safety and ethical considerations in its research endeavors. Through its dedication to medical discovery and education, VUMC plays a pivotal role in shaping the future of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Atlanta, Georgia, United States
Baltimore, Maryland, United States
Washington, District Of Columbia, United States
Nashville, Tennessee, United States
Bethesda, Maryland, United States
Patients applied
Trial Officials
Michael R DeBaun, MD, MPH
Principal Investigator
Vanderbilt University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials